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Abstract
Background: We tested the hypothesis, that intramyocardial injection of mononuclear bone marrow cells combined
with coronary artery bypass grafting (CABG) surgery improves tissue viability or function in infarct regions with non-
viable myocardium as assessed by nuclear imaging techniques.
Methods: Thus far, 7 patients (60 ± 10 [SD] years) undergoing elective CABG surgery after a myocardial infarction were
included in this study. Prior to sternotomy, bone marrow was harvested by sternal puncture. Mononuclear bone marrow
cells were isolated by gradient centrifugation and resuspended in 2 ml volume of Hank's buffered salt solution. At the
end of CABG surgery 10 injections of 0.2 ml each were applied to the core area and borderzones of the infarct. Global
and regional perfusion and viability were evaluated by ECG-gated 99mTc-tetrofosmin myocardial single-photon emission
computed tomograph (SPECT) imaging and 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) in all
study patients < 6 days before and 3 months after the intervention.
Results: Non-viable segments indicating transmural defects were identified in 5 patients. Two patients were found to
have non-transmural defects before surgery. Concomitant surgical revascularisation and bone marrow cell injection was
performed in all patients without major complications. The median total injected mononuclear cell number was 7.0 ×
107 (range: 0.8–20.4). At 3 months 99mTc-tetrofosmin SPECT and 18F-FDG-PET scanning showed in 5 patients (transmural
defect n = 4; non-transmural defect n = 1) no change in myocardial viability and in two patients (transmural defect n =
1, non-transmural defect n = 1) enhanced myocardial viability by 75%. Overall, global and regional LV ejection fraction
was not significantly increased after surgery compared with the preoperative value.
Conclusion: In CABG surgery patients with non-viable segments the concurrent use of intramyocardial cell transfer did
not show any clear improvement in tissue viability or function by means of non-invasive bioimaging techniques.
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Background
Patients with coronary artery disease and left ventricular
(LV) dysfunction presenting with symptoms of either
angina pectoris or heart failure may be considered for cor-
onary artery bypass grafting (CABG) surgery, however, lat-
ter is associated with increased risk in this patient
population [1]. In a subset of patients with dysfunctional
but viable myocardium, both hibernating and stunned,
surgical revascularisation has been shown to improve LV
function, heart failure symptoms, and survival [2,3]. On
the other hand, non-viable myocardium will usually not
resume viability and contractile function after standard
revascularisation strategies [4-6]. Histopathological verifi-
cation of viability in patients is impossible. Thus, the ideal
methodology to assess myocardial viability would pro-
vide accurate non-invasive measurements of perfusion,
metabolism, and cellular membrane integrity in addition
to LV function [4-8]. Nuclear scintigraphy with single-
photon emission computed tomograph (SPECT) imaging
technique is used with various tracers to assess perfusion
and cell integrity as hallmarks of viability. Most fre-
quently, technetium-99m labelled tracers are injected
under resting conditions. In these studies, dysfunctional
segments with tracer uptake > 50% are considered viable
[8]. The best-validated positron emission tomography
(FDG-PET) method for detecting viability assesses both
regional metabolism and perfusion. Metabolism is meas-
ured by uptake of 18F-fluorodeoxyglucose, which is a glu-
cose analogue. It is transported into the cell and is
subsequently converted into a compound that is trapped
within the myocardium. Normal myocardium is charac-
terized by normal flow, normal glucose uptake, and pref-
erential metabolism of fatty acids over glucose. Infarcted,
non-viable myocardium has both decreased flow and glu-
cose uptake [5-7].
The concepts of viability and functional recovery have
been used in many patients after myocardial infarction
and after standard CABG. However, this issue has not yet
been studied in humans in whom stem cell transplanta-
tion was performed as an adjunct to cardiac surgery.
Hence, detecting resumed viability by using nuclear "bio-
imaging" techniques in a formerly non-viable myocardial
region is of clear scientific and clinical significance and
may explain the efficacy of this novel form of cellular ther-
apy that has been developed for myocardial repair in the
last decade. These approaches include stem cell therapy
with various types of stem cells and delivery mechanisms,
in diverse infarction models in animals and humans [9].
In several animal studies, bone marrow cell transplanta-
tion has induced angiogenesis, prevented ventricular dila-
tation, and improved function [10-12]. Clinical studies
which evaluate the use of autologous bone marrow cells
in conjunction with CABG surgery have generally
involved small numbers of patients, and provided prelim-
inary data on the safety and feasibility of targeted implan-
tation, and indicating improved global LV function and
myocardial perfusion [13,14]. However, so far, little is
known when autologous bone marrow cells are targeted
to the core area and borderzones of the myocardial lesion.
In this regard, modern non-invasive bioimaging tech-
niques are of paramount importance to evaluate the true
extent of myocardial restoration and justify the concurrent
use of stem cells and CABG in the same session.
Therefore, the purpose of the present study was to investi-
gate the effects of autologous mononuclear bone marrow
cell transplantation following intraoperative bone mar-
row harvest from the sternum on myocardial viability and
function using as widely accepted reference standards
ECG-gated  99mTc-tetrofosmin SPECT imaging and 18F-
FDG-PET in CABG surgery patients.
Methods
Patients
Following approval by the University of Cologne Human
Ethics Committee (registry #02-025), written, informed
consent was obtained from each patient during the preop-
erative interview. Seven patients with an akinetic infarct
region after previous myocardial infarction (>2 weeks)
scheduled for elective CABG surgery were included in this
study. Patients with unstable angina, valvular disease, or
previous CABG were excluded. Before surgery, all study
patients underwent 99mTc-tetrofosmin SPECT imaging
and 18F-FDG-PET at rest for identification of the presence
and extent of tissue viability in the infarct region. Three
months after CABG surgery and cell transplantation
99mTc-tetrofosmin SPECT and 18F-FDG-PET were repeated
to assess the degree of restoration of perfusion and myo-
cardial recovery in terms of infarct size reduction.
ECG-gated 99mTc-tetrofosmin SPECT
For determination of myocardial viability and LV function
ECG-gated  99mTc-tetrofosmin (Myoview®, Amersham
Buchler GmbH & Co.KG, Braunschweig, Germany)
SPECT images at rest after oral nitrate medication (Isoket
5®, Schwarz Pharma, Monheim, Germany) were acquired.
Six hundred MBq 99mTc-tetrofosmin were injected 10 min
after nitrate administration. SPECT was performed with a
triple-head gamma camera (Prism 3000, Philips Medical
Systems, Best, The Netherlands) using a low-energy high
resolution collimator in step-and-shoot-modus. For the
360 degree arc 40 projections each with 3 degree differ-
ence were acquired with a 64 by 64 matrix and an acqui-
sition time of 30 beats per step. 16 frames were acquired
per cardiac cycle. Transaxial images were reconstructed
with a slice thickness of 4.12 mm using filtered backpro-
jection (low pass filter, 4th order, cutoff frequency 0.30
cycles/pixel). From the transaxial images short axis, hori-
zontal and vertical long axis slices were reconstructed andBMC Medical Imaging 2006, 6:7 http://www.biomedcentral.com/1471-2342/6/7
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a polar map was generated. Attenuation and scatter cor-
rection was not performed. LV function was calculated by
use of the QGS program (Quantitative gated SPECT,
Cedars-Sinai Medical Center, Los Angeles, U.S.A.).
18F-FDG-PET
18F-FDG-PET was performed using a whole-body scanner
(Siemens CTI ECAT EXACT 921, Erlangen, Germany). To
improve myocardial 18F-FDG-uptake, each patient
received a solution of 60 g glucose 1 hour before the
administration of 18F-FDG. Prior to injection of 18F-FDG
blood glucose levels were checked and a short acting
insuline was given according to blood glucose level. Emis-
sion scans over 30 minutes were started 45 minutes after
injection of 370 MBq F-18-FDG. PET data were corrected
for attenuation by using coefficients measured by a trans-
mission scan of 10 minutes duration. PET acquisition data
were reconstructed into transaxial tomograms by filtered
back-projection employing a Hann filter. Transaxial tom-
ograms were reorientated into cardiac short axis, horizon-
tal and vertical long axis slices and converted into a polar
map encompassing the entire left ventricle. Myocardial
segments were defined viable by 18F-FDG-PET if the mean
segmental 18F-FDG-uptake was ≥50% compared to a nor-
mal reference segment.
Image analysis
Image analysis was performed using visual and semi-
quantitative analysis by polar-tomograms. Relative
regional 99mTc-tetrofosmin and 18F-FDG-uptake were cal-
culated as percent uptake of the region of interest with
maximal uptake (normalisation to the 100% perfusion
maximum). To facilitate analysis and to allow clinically
relevant conclusions, widely accepted threshold values
were applied to distinguish between viable and non-via-
ble myocardium. Concerning 99mTc-tetrofosmin SPECT
data, segments were graded as viable if tracer uptake was
above a 50% threshhold for anterior infarcts and a 35%
threshhold for inferior infarcts and as non-viable if tracer
uptake was below 50% or 35% respectively [15]. On 18F-
FDG-PET, segments were graded as viable if tracer uptake
was more than 70% and as non-viable if tracer uptake was
below 50%, segments between 50 and 70% were graded
as non-transmural defects [16,17]. Both methods (99mTc-
tetrofosmin SPECT and 18F-FDG-PET) were separately
evaluated concerning viability. This was feasible by the
concordance of imaging results. An increase in tracer
uptake ≥10% after intervention was considered significant
and to represent improvement (expressed as percent of
the total original defect size). Thereby, the original defect
size was considered 100%. Thus, changes in viability
reflect both, the 99mTc-tetrofosmin SPECT and 18F-FDG-
PET results.
Isolation and cell preparation
Under general anesthesia and prior to sternotomy, 10 ml
of bone marrow was harvested by sternal puncture and
5000 IU Heparin was added (Fig. 1). The cell suspension
was density separated by Ficoll and the mononuclear cell
fraction was washed twice in Hank's buffered salt solution
(HBSS) and resuspended in HBSS to a final volume of 3
ml. While 1 ml was used for flowcytometric characterisa-
tion and microbiological testing, 2 ml were returned to
the operating room for intramyocardial injection.
Operative technique and cell transplantation
Patients underwent CABG using standard operative tech-
niques. Myocardial preservation was performed by means
of systemic normothermia and warm blood cardioplegia
into the ascending aorta before each graft. After comple-
tion of the proximal anastomoses, we mobilized the beat-
ing and unloaded heart on CPB and injected the
suspension of mononuclear bone marrow cells via 10
injections of 0.2 ml each into the infarct region using a
standard insulin syringe with a 20-gauge needle (Fig. 2).
Nine injections were applied to the periphery of the inf-
arct zone and one injection was applied to the center of
the infarct. The targeted injections to infarcted region cor-
responded to the bioimaging findings which permitted in
most cases intraoperative visualization of myocardial scar.
We tried to inject the cells allways into the mid-myocar-
dium. The median total injected mononuclear cell
number per patient was 7.0 ± 6.4 × 107 (range: 0.8–20.4).
The median percentage of CD34+ progenitor cells was
1.95 ± 0.82% and CD34+/CD133+ 0.8 ± 0.2%, while
CD34+/KDR+ endothelial progenitor cells were found
with a frequency of 0.02 ± 0.006%.
Bone marrow was harvested by sternal puncture prior to  sternotomy Figure 1
Bone marrow was harvested by sternal puncture prior to 
sternotomy.BMC Medical Imaging 2006, 6:7 http://www.biomedcentral.com/1471-2342/6/7
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Statistical analysis
All data presented are mean ± standard deviation (SD).
Results
Patients
Seven patients (5 men and 2 women; mean age of 60 ± 10
years [range: 49 to 76 years]) with angiographically
proven coronary artery disease scheduled for CABG sur-
gery were enrolled in this study. All patients had a history
of myocardial infarction, and 3 patients had a history of
congestive heart failure requiring hospitalisation. The site
of myocardial infarction was the posterior wall in 5
patients and the anterior wall in 2. On coronary angiogra-
phy, 6 patients had three-vessel disease, and 1 patient had
two-vessel disease with stenoses of the major coronary
arteries of more than 75%. Every patient had a distinct
akinetic infarct region determined by left ventriculogra-
phy or echocardiography, 3 weeks to 8 months after a pre-
vious infarction. The LV ejection fraction was 41 ± 7%
(range: 31 to 51%). The interval between baseline nuclear
imaging and subsequent revascularisation was < 6 days.
Clinical and imaging data are shown in Table 1.
Surgery
An average of 3 ± 1 arteries were grafted (range from 2 to
4). CABG was performed in all patients using the left
internal thoracic artery, that was anastomosed to left ante-
rior descending (LAD) (n = 6) and to left circumflex coro-
nary arteries (n = 1). Radial arterial grafts were inserted to
left circumflex coronary arteries (n = 3). Venous grafts
were used to right coronary arteries (n = 4) and to left cir-
cumflex arteries (n = 4) and to diagonal branches (n = 4).
All patients were successfully separated from cardiopul-
monary bypass. No intraaortic balloon counterpulsation
became necessary. No perioperative myocardial infarction
occurred.
Clinical outcomes
Periprocedurally, no major complications occurred in any
of our patients. All patients remained free of angina at 3
months follow-up. There were no deaths or subsequent
need for revascularisation. One patient was found to have
a LV thrombus which had resolved after anticoagulation
therapy at the next follow-up. Holter electrocardiograms
showed no ventricular arrhythmia up to 3 months after
Mononuclear bone marrow cells were applied to the borderzone and the core area of the infarction (arrows) Figure 2
Mononuclear bone marrow cells were applied to the borderzone and the core area of the infarction (arrows).BMC Medical Imaging 2006, 6:7 http://www.biomedcentral.com/1471-2342/6/7
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treatment. In addition, echocardiography did not show
calcification after intramyocardial cell transplantation.
Changes in myocardial viability and function
The relationship between myocardial infarction and the
amount of viable myocardium is presented in Table 1.
Non-viable segments indicating transmural defects by
99mTc-tetrofosmin SPECT and 18F-FDG-PET scans were
identified in 5 patients. Two patients were found to have
non-transmural defects before surgery. As expected, the
patients showed concordant perfusion defects before
revascularisation. At 3 months 99mTc-tetrofosmin SPECT
and 18F-FDG-PET scanning showed in 5 patients (trans-
mural defect n = 4; non-transmural defect n = 1) no
change in myocardial viability. Nuclear bioimaging
showed in two patients (transmural defect n = 1, non-
transmural defect n = 1) enhanced myocardial viability by
75%. Only in the latter patient with a non-transmural
defect (Figs. 3, 4, 5) LV ejection fraction improved (31%
vs. 60%) after combined CABG and cell therapy. How-
ever, overall global and regional LV ejection fraction was
not significantly increased at 3 months after surgery com-
pared with the preoperative value (Tabl. 2).
Discussion
The main findings of our study question the efficacy of
autologous cell transplantation for myocardial restoration
in CABG surgery patients. This was proven by means of
non-invasive bioimaging techniques which showed no
evidence of clear improvement in tissue viability or func-
tion within akinetic and non-viable infarct regions.
The differentiation between viable myocardium and scar
tissue has important clinical implications, because in
patients with viable myocardium, revascularisation is
likely to result in improvement of regional and global LV
function, heart failure symptoms, and long-term progno-
sis [2,3]. In contrast, regional LV dysfunction arising from
transmural myocardial infarction with non-viable myo-
cardium may be irreversible after revascularisation [4-6].
To treat this portion of the ischemic heart muscle a novel
therapeutic strategy using bone marrow cells has been
proposed as a potential alternative treatment for such
patients, because these cells have been shown to improve
structure and function in experimental myocardial infarc-
tion [11,12]. Thereby, locally released paracrine factors
may act by promoting angiogenesis [10].
Preliminary data in small patient numbers in whom bone
marrow-derived cells have been injected into myocardial
tissue suggest the safety and feasibility of cell transplanta-
tion. Hamano et al. [13] injected autologous mononu-
clear bone marrow cells directly into ungraftable
myocardial territories during CABG surgery in 5 patients.
Postoperative evaluation revealed no short-term toxicity
or adverse events and the engrafted cells seemed to con-
tribute to improved perfusion observed in these territo-
ries. In a similar study by Stamm et al. [14], injection of
AC 133+ bone marrow cells in the peri-infarct zone in
conjunction with CABG in 12 patients resulted in signifi-
cantly improved global LV function as well as improved
perfusion of the infarcted myocardium assessed by thal-
lium scans. Tse et al. [18] found improvement in myocar-
dial perfusion and segmental contractility as assessed by
cardiac magnetic resonance imaging in ischemic myocar-
dial segments of 8 patients treated with sole catheter-
based intramyocardial implantation of autologous mono-
nuclear bone marrow cells. Silva et al. [19] used transend-
ocardial delivery of autologous bone marrow-derived
mononuclear cells in heart transplant candidates with via-
ble ischemic myocardium. After cell therapy exercise
capacity improved, and 4 of the 5 patients were no longer
eligible for cardiac transplantation. Most recently pub-
lished studies [20] reported short-term functional
improvement of transplantation of mononuclear bone
marrow cells through an intracoronary delivery system in
patients after successful percutaneous coronary interven-
tion for acute ST-segment elevation myocardial infarct. In
most of the studies the ischemic regions injected with cells
were still viable and thus, despite the presence of clinically
Table 1: Clinical and imaging patient data
Pat Myocardial defect Bypass grafts to Injection location MNC number CD34+ cell 
fraction
Changes in viability
1 Transmural LAD, D, OM, RCA Posterolateral 4.2 × 107 1.41% None
2 Non-transmural LAD, OM1, OM2 Anterior, apex 0.8 × 107 1.42% 75%
3 Transmural LAD, D, RCA Posterobasal 20.4 × 107 1.42% 75%
4 Transmural LAD, D, OM1 Posterobasal 7.0 × 107 1.26% None
5 Transmural LAD, D, OM, RCA Apex 2.8 × 107 3.28% None
6 Transmural OM1, OM2 Posterolateral 7.6 × 107 1.94% None
7 Non-transmural LAD, OM, RCA Posterior 6.0 × 107 2.93% None
D: diagonal coronary artery; LAD: left anterior descending coronary artery; OM: obtuse marginal coronary artery; MNC: mononuclear cell; Pat: 
patient; RCA: right coronary artery.BMC Medical Imaging 2006, 6:7 http://www.biomedcentral.com/1471-2342/6/7
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promising data, no conclusion can be drawn for the revi-
talising capacity of bone marrow cells.
In contrast, in our study injections were performed to
non-viable myocardium. We did not find evidence that
mononuclear bone marrow cells in combination with
CABG are capable of restoring viability or function in
patients with formerly non-viable infarcted myocardium.
Transepicardial cell injection during open heart surgery
into the core and border zone of infarct scar resulted in
enhanced myocardial viability by 75% as determined by
99mTc-tetrofosmin SPECT and 18F-FDG-PET only in one
patient. Though this finding is notable in that metaboli-
cally non-viable segments (99mTc-tetrofosmin SPECT and
18F-FDG uptake ≤50%) usually do not improve after
revascularisation [4-6], the contribution of transplanted
mononuclear bone marrow cells to resumed viability is
unclear. In this study the median total injected mononu-
clear cell number as well as the median percentage and the
range of CD34+, CD34+/CD133+ and CD34+/KDR+ cells
were found to be in concordance with published data
from other groups. Interestingly, the number of injected
cells did not correlate with the change in myocardial via-
bility.
We used 99mTc-tetrofosmin SPECT and 18F-FDG-PET as
widely accepted reference standards for the non-invasive
assessment of myocardial ischemia and viability [16,17].
Different characteristics such as intact perfusion, cell
membrane integrity, and preserved glucose metabolism
form the basis for tissue characterisation by these different
nuclear bioimaging modalities, that allow to distinguish
transmural scar from dysfunctional but viable myocardial
tissue [2,4-8]. Thus, scintigraphic viability techniques
using combined assessment of perfusion and metabolism
offer an advantage over perfusion imaging alone, as for
example used by Stamm et al. [14]. However, overall we
did not detect global LV function improvement at 3
months after cell transplantation and CABG surgery. From
the preliminary data available no difference in regional
LVEF before and after surgery could be demonstrated.
However, differences in regional LVEF might be better evl-
uated with cine magnetic resonance imaging (MRI) [7].
The major limitations of this ongoing study are the small
numbers of patients and the absence of a control group as
for most studies published so far. Importantly, all patients
underwent cell implantation during bypass surgery.
Therefore, an effect of improved myocardial blood flow
due to surgical revascularisation itself on the viability as
assessed by 99mTc-tetrofosmin SPECT and 18F-FDG-PET
Vertical long axis 99mTc-tetrofosmin SPECT images of patient with myocardial infarction Figure 3
Vertical long axis 99mTc-tetrofosmin SPECT images of patient with myocardial infarction. (A) Perfusion defect at apex and ante-
rior wall before surgical therapy. (B) Three months after cell transplantation and CABG, the apex and anterior wall (arrows) 
were considered to have normal perfusion.BMC Medical Imaging 2006, 6:7 http://www.biomedcentral.com/1471-2342/6/7
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may be possible. Nevertheless, the preliminary findings
reported here, focussing on myocardial viability with
nuclear imaging techniques may contribute significantly
to the field of stem cell therapy for the treatment of
postinfarct patients, since the distinction between viable
myocardium and irreversibly damaged scar tissue supple-
mentary to clinical and angiographic data is of profound
value. However, given the current incomplete knowledge
on the mechanisms of transplanted adult stem cells in
vivo, potential benefits and disadvantages must be con-
sidered in selecting candidate cells and patients for clini-
cal trials. Clearly, there is a need for randomized, double-
blind trials involving large numbers of patients before
autologous bone marrow stem cells can be considered a
clinically relevant option of therapy.
Vertical long axis (A, B) and short axis (C, D) 18F-FDG-PET images of patient with myocardial infarction Figure 4
Vertical long axis (A, B) and short axis (C, D) 18F-FDG-PET images of patient with myocardial infarction. Non-transmural 
defect at apex and anterior wall before surgical therapy (A, C). Three months after cell transplantation and CABG, anterior 
wall and apex showed increased viability (arrows) in infracted area (B, D). EF changed from 31% to 60%.BMC Medical Imaging 2006, 6:7 http://www.biomedcentral.com/1471-2342/6/7
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Conclusion
Our findings demonstrate that intramyocardial injection
of autologous mononuclear bone marrow cells during
CABG surgery does not contribute to enhanced myocar-
dial viability or function of akinetic and non-viable infarct
regions. The intraoperative bone marrow harvest from the
sternum is an efficient and safe method to collect cells for
myocardial cell transfer. Further clinical studies are
needed to assess the validity of this therapeutic strategy in
conjunction with currently used therapies.
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